Vidal C, Gude F, Boquete O, Fernández-Merino M C, Meijide L M, Rey J, Lojo S, González-Quintela A
Department of Allergy, Internal Medicine. Complejo Hospitalario Universitario de Santiago, Spain.
J Investig Allergol Clin Immunol. 2005;15(2):124-30.
Phadiatop is a commercially available qualitative serological test employed for screening of allergic sensitization in patients with suspected allergic diseases.
The study evaluated the diagnostic accuracy of Phadiatop for the diagnosis of allergic sensitization in a general adult population.
A total of 469 subjects from the population of A-Estrada (Spain) were selected by age-stratified random sampling (age range, 18-92 years). Phadiatop test (Uni-CAP method) was performed in serum samples from 465 of these subjects. Skin prick tests to a panel of 13 relevant aeroallergens in the studied area (including mites, pollens, moulds, and animal dander) were employed as the reference diagnostic procedure. Subjects with at least a positive skin prick test (> or =4 mm, n= 120) were considered to have allergic sensitization.
Phadiatop sensitivity was 70.8% (95% CI 61.7-78.6%), specificity 90.7% (95% CI 87.0-93.5%), positive predictive value 72.6% (95% CI 63.5-80.3%), negative predictive value 89.9% (95% CI 86.2-92.8%), global accuracy 85.6% (95% CI 82.0-88.6%), negative likelihood ratio 0.3 (95% CI 0.2-0.4), and positive likelihood ratio 7.6 (95% CI 5.4-10.8). A high proportion of false-positive Phadiatop cases showed (a) increased total serum IgE levels, (b) significant alcohol consumption, and (c) small-sized (below the diagnostic cut-off) wheal reactions on SPT. A high proportion of false-negative Phadiatop cases showed exclusive storage mite sensitization. Sensitivity and positive predictive value of Phadiatop were somewhat higher among individuals with a history of nasal or bronchial symptoms.
Phadiatop is a valuable tool for the diagnosis of allergic sensitization in a general adult population. However, limitations of the test should be taken into account in similar surveys.
Phadiatop是一种可用于筛查疑似过敏性疾病患者过敏致敏情况的商业化定性血清学检测方法。
本研究评估了Phadiatop在普通成年人群中诊断过敏致敏的诊断准确性。
通过年龄分层随机抽样(年龄范围18 - 92岁)从西班牙A - Estrada人群中选取了469名受试者。对其中465名受试者的血清样本进行了Phadiatop检测(Uni - CAP方法)。采用对研究区域内一组13种相关气传变应原(包括螨虫、花粉、霉菌和动物皮屑)的皮肤点刺试验作为参考诊断程序。至少有一次皮肤点刺试验阳性(≥4毫米,n = 120)的受试者被认为有过敏致敏。
Phadiatop的敏感性为70.8%(95%可信区间61.7 - 78.6%),特异性为90.7%(95%可信区间87.0 - 93.5%),阳性预测值为72.6%(95%可信区间63.5 - 80.3%),阴性预测值为89.9%(95%可信区间86.2 - 92.8%),总体准确性为85.6%(95%可信区间82.0 - 88.6%),阴性似然比为0.3(95%可信区间0.2 - 0.4),阳性似然比为7.6(95%可信区间5.4 - 10.8)。Phadiatop检测出现高比例假阳性的情况表现为:(a)血清总IgE水平升高,(b)大量饮酒,以及(c)皮肤点刺试验中出现小面积(低于诊断临界值)风团反应。Phadiatop检测出现高比例假阴性的情况表现为单纯的粉尘螨致敏。在有鼻或支气管症状病史的个体中,Phadiatop的敏感性和阳性预测值略高。
Phadiatop是诊断普通成年人群过敏致敏的一种有价值的工具。然而,在类似调查中应考虑该检测方法的局限性。